Skip to main content

Table 1 Baseline demographic and clinical data

From: Impact of stress hyperglycemia ratio, derived from glycated albumin or hemoglobin A1c, on mortality among ST-segment elevation myocardial infarction patients

 

Total

SHR1

Q1 (n = 411)

Q2 (n = 409)

Q3 (n = 412)

Q4 (n = 411)

Ischemia time, hours

6.13 (4.00, 10.78)

7.00 (4.23, 11.00)

6.57 (4.00, 11.00)

6.00 (4.00, 10.04)

6.00 (3.84, 10.12)

Age, years

62.46 ± 12.58

65.14 ± 12.39

61.59 ± 12.71

60.64 ± 12.59

62.46 ± 12.24

Sex, male, n (%)

1323 (80.52)

325 (79.08)

335 (81.91)

349 (84.71)

314 (76.40)

Smoking history, n (%)

 Current

787 (47.90)

179 (43.55)

209 (51.10)

222 (53.88)

177 (43.07)

 Past

128 (7.79)

31 (7.54)

27 (6.60)

33 (8.01)

37 (9.00)

Medical history, n (%)

 Hypertension

928 (56.48)

228 (55.47)

211 (51.59)

233 (56.55)

256 (62.29)

 Diabetes

556 (33.84)

130 (31.63)

106 (25.92)

115 (27.91)

205 (49.88)

 Hypercholesteremia

386 (23.49)

72 (17.52)

88 (21.52)

111 (26.94)

115 (27.98)

 ASCVD

231 (14.06)

71 (17.27)

52 (12.71)

47 (11.41)

61 (14.84)

Laboratory examinations

 eGFR, ml/min/1.73m2

95.68 ± 18.14

92.99 ± 18.02

97.26 ± 17.44

96.89 ± 16.04

95.58 ± 20.53

 FBG, mmol/L

7.01 ± 3.05

5.34 ± 1.51

5.97 ± 1.50

6.76 ± 1.92

9.94 ± 4.06

 HbA1c, %

6.58 ± 1.54

6.56 ± 1.54

6.30 ± 1.22

6.43 ± 1.38

7.04 ± 1.85

 GA, %

16.10 ± 4.43

17.08 ± 4.77

15.52 ± 3.78

15.37 ± 4.35

16.42 ± 4.55

 Triglycerides, μmol/L

1.38 (1.02, 2.04)

1.27 (0.95, 1.76)

1.40 (1.06, 2.01)

1.42 (1.01, 2.07)

1.52 (1.06, 2.25)

HDL, μmol/L

1.05 ± 0.25

1.06 ± 0.26

1.05 ± 0.27

1.04 ± 0.23

1.05 ± 0.26

LDL, μmol/L

2.76 ± 0.95

2.57 ± 0.92

2.82 ± 0.92

2.80 ± 0.84

2.85 ± 1.08

LVEF, %

51.45 ± 16.14

52.69 ± 16.83

52.95 ± 15.36

51.65 ± 16.36

48.48 ± 15.61

Procedural information

Culprit vessel, n (%)

 LM

18 (1.10)

4 (0.97)

1 (0.24)

2 (0.49)

11 (2.68)

 LAD

885 (53.86)

223 (54.26)

209 (51.10)

222 (53.88)

231 (56.20)

 LCX

177 (10.77)

47 (11.44)

58 (14.18)

38 (9.22)

34 (8.27)

 RCA

563 (34.27)

137 (33.33)

141 (34.47)

150 (36.41)

135 (32.85)

Multivessel disease, n (%)

 Two-vessel

407 (24.77)

114 (27.74)

92 (22.49)

102 (24.76)

99 (24.09)

 Three-vessel

263 (16.01)

60 (14.60)

66 (16.14)

63 (15.29)

74 (18.00)

TIMI flow, n (%)

 0

665 (40.47)

123 (29.93)

154 (37.65)

193 (46.84)

195 (47.45)

 1

43 (2.62)

9 (2.19)

12 (2.93)

11 (2.67)

11 (2.68)

 2

86 (5.23)

25 (6.08)

18 (4.40)

22 (5.34)

21 (5.11)

 3

849 (51.67)

254 (61.80)

225 (55.01)

186 (45.15)

184 (44.77)

Thrombectomy, n (%)

774 (47.17)

136 (33.17)

182 (44.61)

230 (55.83)

226 (54.99)

Number of stents

1.47 ± 0.80

1.54 ± 0.92

1.47 ± 0.79

1.52 ± 0.80

1.37 ± 0.67

Diameter of stents

3.00 (2.75, 3.50)

3.00 (2.50, 3.50)

3.00 (2.75, 3.50)

3.00 (2.75, 3.50)

3.00 (2.75, 3.50)

Length of stents

31.50 (24.00, 46.00)

32.00 (23.00, 45.25)

32.00 (23.00, 48.00)

32.00 (24.00, 50.00)

30.00 (24.00, 40.00)

Medication, n (%)

 Statins

1598 (97.26)

406 (98.78)

403 (98.53)

404 (98.06)

385 (93.67)

 ACEI or ARB

1302 (79.25)

318 (77.37)

338 (82.64)

330 (80.10)

316 (76.89)

 β-Blocker

1506 (91.66)

375 (91.24)

382 (93.40)

377 (91.50)

372 (90.51)

  1. Data are means ± SD, median (interquartile range), or n (%)
  2. ACEI Angiotensin converting enzyme inhibitors, ARB Angiotensin II receptor blockers, FBS fasting blood sugar, GA glycated albumin, HbA1c Glycosylated Hemoglobin, Type A1c, HDL-C High density lipoprotein cholesterol, LAD Left anterior descending artery, LCX Left circumflex artery, LDL-C Low density lipoprotein cholesterol, LM left main artery, LVEF Left ventricular ejection fraction, RCA Right coronary artery, SHR stress hyperglycemia ratio, TIMI Thrombolysis in myocardial infarction